Fischer medical ventures Limited has announced a key management appointment following its Board of Directors meeting held on March 24, 2026. The company has appointed Mr. Balaji Gandla as Company Secretary and Compliance Officer, marking an important addition to its leadership team.

Board Meeting Outcomes

The Board of Directors approved the appointment during their meeting on March 24, 2026, which was conducted from 11:10 AM (IST) to 12:20 PM (IST). The appointment was made pursuant to Section 203 of the Companies Act, 2013 and Regulation 6 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Professional Background

Mr. Balaji Gandla brings substantial expertise to his new role. He is a qualified Company Secretary and an Associate Member of the Institute of Company Secretaries of India (ICSI). His educational background includes a Bachelor of Commerce degree from the University of Madras, Chennai.

Key Qualifications and Experience

• Over a decade of professional experience in corporate governance
• Specialization in Secretarial Compliance and Regulatory Affairs
• Proven track record in managing end-to-end secretarial and compliance functions
• Experience with both listed and unlisted companies
• Expertise in liaison and correspondence with regulatory authorities including ROC, SEBI, BSE, and NSE

Dual Responsibilities

In addition to his role at Fischer Medical Ventures Limited, Mr. Gandla will simultaneously serve as Company Secretary of the company's wholly owned subsidiary, Time Medical International Ventures (India) Private Limited, effective from the same date.

Regulatory Compliance

The appointment fulfills the company's obligations under various regulatory frameworks and demonstrates Fischer Medical Ventures Limited's commitment to maintaining robust corporate governance standards. The company has duly informed both BSE Limited and the National Stock Exchange of India Limited about this key management personnel change as required under SEBI regulations.

Fischer Medical Ventures Limited has announced the opening of a special window for shareholders to re-lodge transfer requests for physical shares that were previously rejected or returned due to various deficiencies. The initiative demonstrates the company's commitment to facilitating smooth share transfer processes for its investors.

Special Window Details

The company has established a dedicated timeframe for addressing previously unsuccessful share transfer requests. This special window provides shareholders with an opportunity to rectify and resubmit their transfer documentation.

Regulatory Compliance

The special window initiative follows regulatory guidelines and demonstrates Fischer Medical Ventures' adherence to SEBI requirements. The company has taken this step in compliance with specific regulatory directives aimed at facilitating share transfer processes.

Public Notification

Fischer Medical Ventures has ensured widespread awareness of this initiative through strategic newspaper publications. The company published advertisements in both English and regional language publications to reach a diverse shareholder base.

The newspaper advertisements were published on March 12, 2026 in:

• Financial Express (English daily with electronic edition)
• Vishalandra (Telugu daily with electronic edition)

Shareholder Action Required

Shareholders who have previously faced issues with physical share transfers are advised to take advantage of this special window. The company has provided clear guidance on the submission process and documentation requirements.

Key actions for affected shareholders:

• Review previously rejected or returned transfer requests
• Gather required documentation as specified by the company
• Submit complete documentation to the company's Registrar and Share Transfer Agent
• Ensure submission within the specified window period

Corporate Communication

The announcement was formally communicated to stock exchanges as part of the company's disclosure obligations. Fischer Medical Ventures submitted the notification to both BSE Limited and National Stock Exchange of India Limited on March 12, 2026, ensuring transparency and regulatory compliance in its communication with stakeholders.